Fiera Capital Corp Decreases Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Fiera Capital Corp lowered its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 5.9% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 359,996 shares of the biotechnology company's stock after selling 22,649 shares during the quarter. Fiera Capital Corp owned about 0.38% of Sarepta Therapeutics worth $44,960,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Fifth Third Wealth Advisors LLC purchased a new stake in shares of Sarepta Therapeutics during the 2nd quarter worth approximately $607,000. Teachers Retirement System of The State of Kentucky purchased a new stake in Sarepta Therapeutics in the second quarter valued at $4,771,000. Securian Asset Management Inc. acquired a new position in Sarepta Therapeutics in the second quarter valued at $1,187,000. Natixis Advisors LLC acquired a new position in Sarepta Therapeutics in the second quarter valued at $1,918,000. Finally, Oppenheimer Asset Management Inc. grew its holdings in shares of Sarepta Therapeutics by 32.0% during the first quarter. Oppenheimer Asset Management Inc. now owns 3,604 shares of the biotechnology company's stock worth $467,000 after purchasing an additional 874 shares during the last quarter. Hedge funds and other institutional investors own 86.68% of the company's stock.

Sarepta Therapeutics Price Performance

Sarepta Therapeutics stock traded down $2.74 during midday trading on Friday, reaching $117.68. The company's stock had a trading volume of 532,508 shares, compared to its average volume of 1,230,146. The firm has a market capitalization of $11.22 billion, a PE ratio of 267.61 and a beta of 0.81. Sarepta Therapeutics, Inc. has a fifty-two week low of $75.85 and a fifty-two week high of $173.25. The stock's 50 day simple moving average is $126.20 and its 200 day simple moving average is $132.77. The company has a debt-to-equity ratio of 1.05, a quick ratio of 3.19 and a current ratio of 3.90.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last announced its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter, beating the consensus estimate of $0.01 by $0.06. The firm had revenue of $362.90 million during the quarter, compared to analysts' expectations of $394.38 million. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The business's revenue for the quarter was up 38.9% compared to the same quarter last year. During the same quarter last year, the business earned ($0.27) earnings per share. On average, equities research analysts forecast that Sarepta Therapeutics, Inc. will post 1.48 earnings per share for the current year.

Insider Buying and Selling at Sarepta Therapeutics

In other news, Director Michael Andrew Chambers purchased 37,038 shares of the firm's stock in a transaction dated Friday, August 16th. The shares were acquired at an average price of $133.80 per share, with a total value of $4,955,684.40. Following the purchase, the director now directly owns 284,034 shares of the company's stock, valued at $38,003,749.20. The trade was a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. In other Sarepta Therapeutics news, Director Michael Andrew Chambers acquired 37,038 shares of the firm's stock in a transaction that occurred on Friday, August 16th. The shares were acquired at an average cost of $133.80 per share, for a total transaction of $4,955,684.40. Following the transaction, the director now directly owns 284,034 shares of the company's stock, valued at approximately $38,003,749.20. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Ian Michael Estepan sold 5,985 shares of the firm's stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the transaction, the chief financial officer now owns 33,946 shares of the company's stock, valued at $4,662,822.56. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages recently issued reports on SRPT. Piper Sandler decreased their target price on Sarepta Therapeutics from $205.00 to $200.00 and set an "overweight" rating for the company in a research report on Thursday, August 8th. Raymond James reiterated an "outperform" rating and issued a $150.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, October 10th. Robert W. Baird lowered their target price on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an "outperform" rating on the stock in a research report on Thursday. Jefferies Financial Group started coverage on shares of Sarepta Therapeutics in a research report on Monday, October 21st. They issued a "buy" rating and a $165.00 price target for the company. Finally, Cantor Fitzgerald upgraded shares of Sarepta Therapeutics from a "neutral" rating to an "overweight" rating and increased their price target for the stock from $152.00 to $167.00 in a research note on Thursday. One equities research analyst has rated the stock with a hold rating, twenty have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Sarepta Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $181.33.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.